Bridgewater Associates - BIO-TECHNE CORP ownership

BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 524 filers reported holding BIO-TECHNE CORP in Q3 2022. The put-call ratio across all filers is 0.22 and the average weighting 0.2%.

About BIO-TECHNE CORP

Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.

Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.

In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.

Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.

Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

Quarter-by-quarter ownership
Bridgewater Associates ownership history of BIO-TECHNE CORP
ValueSharesWeighting
Q3 2023$838,486
-14.3%
12,318
+2.8%
0.01%
-16.7%
Q2 2023$978,499
-75.1%
11,987
-77.4%
0.01%
-75.0%
Q1 2023$3,931,031
+740.2%
52,986
+838.6%
0.02%
+700.0%
Q4 2022$467,858
-58.4%
5,645
+42.5%
0.00%
-50.0%
Q3 2022$1,125,000
-30.7%
3,962
-15.4%
0.01%
-14.3%
Q2 2022$1,623,000
+4.3%
4,681
+30.3%
0.01%
+16.7%
Q1 2022$1,556,000
+191.4%
3,593
+248.2%
0.01%
+100.0%
Q4 2021$534,000
+14.8%
1,032
+7.5%
0.00%0.0%
Q3 2021$465,000
+12.6%
960
-54.5%
0.00%
-25.0%
Q3 2019$413,000
-76.7%
2,110
-82.8%
0.00%
-75.0%
Q4 2018$1,775,000
+349.4%
12,267
+534.6%
0.02%
+300.0%
Q3 2018$395,000
-65.0%
1,933
-74.7%
0.00%
-63.6%
Q2 2018$1,130,000
-12.7%
7,636
-10.9%
0.01%
-8.3%
Q1 2018$1,294,000
+448.3%
8,567
+338.2%
0.01%
+500.0%
Q3 2017$236,000
-58.8%
1,955
-59.9%
0.00%
-60.0%
Q2 2017$573,000
+157.0%
4,878
+96.9%
0.01%
+66.7%
Q4 2015$223,000
-81.4%
2,478
-80.9%
0.00%
-81.2%
Q3 2015$1,200,000
+179.7%
12,978
+203.1%
0.02%
+433.3%
Q1 2015$429,000
+16.6%
4,282
+7.5%
0.00%0.0%
Q4 2014$368,0003,9820.00%
Other shareholders
BIO-TECHNE CORP shareholders Q3 2022
NameSharesValueWeighting ↓
Broadcrest Asset Management, LLC 300,000$24,489,00021.05%
Montanaro Asset Management Ltd 388,800$31,737,7445.02%
Sandhill Capital Partners LLC 502,447$41,014,7753.74%
Brown Capital Management 3,160,892$258,023,6143.66%
DF DENT & CO INC 3,275,617$267,388,6403.62%
Ownership Capital B.V. 2,282,104$186,288,1503.26%
Jackson Square Partners, LLC 1,361,789$111,162,8363.24%
STONE RUN CAPITAL, LLC 88,135$7,194,4603.20%
Pembroke Management, LTD 339,591$27,720,8132.99%
Summit Creek Advisors LLC 283,693$23,157,8602.90%
View complete list of BIO-TECHNE CORP shareholders